User profiles for "author:Marcelo V Negrao"
 | Marcelo V. NegraoMD Anderson Cancer Center Verified email at mdanderson.org Cited by 2992 |
[HTML][HTML] Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation
Abstract Background Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds
KRASG12C, locking it in its inactive state. Adagrasib showed clinical activity and had an …
KRASG12C, locking it in its inactive state. Adagrasib showed clinical activity and had an …
[HTML][HTML] Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Purpose: Osimertinib was initially approved for T790M-positive non–small cell lung cancer
(NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However …
(NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However …
[HTML][HTML] Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
MV Negrao, F Skoulidis, M Montesion… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene
alterations typically derive limited benefit from immune checkpoint blockade (ICB), which …
alterations typically derive limited benefit from immune checkpoint blockade (ICB), which …
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
MV Negrao, HA Araujo, G Lamberti, AJ Cooper… - Cancer discovery, 2023 - AACR
Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRAS G12C-
mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 …
mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 …
[PDF][PDF] Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
We report a phase II study of 50 advanced non-small cell lung cancer (NSCLC) patients with
point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The …
point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The …
[HTML][HTML] Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC
Introduction Programmed death-ligand 1 (PD-L1) expression may vary in different disease
sites and at different time points of the disease course. We aimed to investigate PD-L1 …
sites and at different time points of the disease course. We aimed to investigate PD-L1 …
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
MB Nilsson, H Sun, J Robichaux, M Pfeifer… - Science translational …, 2020 - science.org
Acquired resistance to tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor
(EGFR) remains a clinical challenge. Especially challenging are cases in which resistance …
(EGFR) remains a clinical challenge. Especially challenging are cases in which resistance …
Neoadjuvant targeted therapy in resectable non-small cell lung cancer: current and future perspectives
JM Lee, CJ McNamee, E Toloza, MV Negrao… - Journal of Thoracic …, 2023 - Elsevier
The standard of care (SoC) for medically operable patients with early-stage (stage I–IIIB)
non-small cell lung cancer (NSCLC) is surgery combined with (neo) adjuvant systemic …
non-small cell lung cancer (NSCLC) is surgery combined with (neo) adjuvant systemic …
[HTML][HTML] Poziotinib for patients with HER2 exon 20 mutant non–small-cell lung cancer: Results from a phase II trial
YY Elamin, JP Robichaux, BW Carter… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Targeted therapies against non–small-cell lung cancer (NSCLC) harboring
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …